Keyphrases
Biomarker Testing
100%
Targeted Treatment
100%
Mild Cognitive Impairment
100%
Cost-effectiveness Analysis
100%
Cerebrospinal Fluid Biomarkers
100%
Risk Level
44%
Quality-adjusted Life Years
33%
Patient Risk
33%
Alzheimer's Disease
22%
Treatment Efficacy
22%
Incremental Cost-effectiveness Ratio
22%
Cost-effectiveness
11%
Early Intervention
11%
Low Risk
11%
Treatment Decisions
11%
Patient Identification
11%
Parameter Uncertainty
11%
Mild Alzheimer's Disease
11%
Risk Identification
11%
Life Cost
11%
Best Available Evidence
11%
Societal Perspective
11%
Probabilistic Sensitivity Analysis
11%
State Transition Model
11%
Cost-effective Strategy
11%
Early Targeted Treatment
11%
Project Lifetime
11%
Treatment Level
11%
Test-and-treat Strategies
11%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Mild Cognitive Impairment
100%
Alzheimer's Disease
33%
Combination Therapy
22%
Biochemistry, Genetics and Molecular Biology
Quality Adjusted Life Year
100%
Lifespan
33%